Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis
Background When formulating topical products to treat skin diseases and addressing general skin health and cosmesis, most of the focus has traditionally been placed on how any given ingredient may impact the structure, function, and health of human skin elements. However, recent research is beginnin...
Gespeichert in:
Veröffentlicht in: | Journal of cosmetic dermatology 2023-03, Vol.22 (3), p.1031-1045 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1045 |
---|---|
container_issue | 3 |
container_start_page | 1031 |
container_title | Journal of cosmetic dermatology |
container_volume | 22 |
creator | Rhee, Mun Su Alqam, Mona L. Jones, Brian C. Phadungpojna, Sasima Day, Doris Hitchcock, Thomas M. |
description | Background
When formulating topical products to treat skin diseases and addressing general skin health and cosmesis, most of the focus has traditionally been placed on how any given ingredient may impact the structure, function, and health of human skin elements. However, recent research is beginning to highlight the importance of the skin microbiome in relation to certain skin conditions and general cosmesis. Cutibacterium acnes is one of the most prolific skin‐specific bacterial species. Research has shown that the species is divided into subspecies, some of which are thought to be beneficial to the skin. This paper aims to determine the efficacy of strainXYCM42, a C. acnes subspecies defendens derived strain designed to improve the health and appearance of the skin.
Methods
In vitro studies were performed on human keratinocyte and fibroblast monolayers, human peripheral blood mononuclear cells (PBMC), and skin explants to elucidate the effects of live XYCM42 cells and their ferment on human skin cells and tissues. Subsequently, clinical studies were performed using XYCM42‐based topical regimens designed to deliver and support the engraftment of live XYCM42 cells onto subjects' skin. Two studies were performed, a 3‐week pilot study (n = 10) and a 8‐week pivotal study (n = 121). In the latter, 32 subjects were enrolled for an in‐clinic portion for efficacy evaluation, with clinic visits occurring at Baseline, Week 1, Week 4, and Week 8.
Results
In vitro data suggest that XYCM42 and its ferment filtrate have potential to provide benefits to the skin via antioxidant, anti‐inflammatory, and select antimicrobial activities. Clinical observation demonstrated that a XYCM42‐containing regimen supports a healthy skin environment, promotes increased skin hydration, decreases erythema, calms the skin, and regulates sebum production.
Conclusion
These studies provide further evidence that specific strains of C. acnes, such as XYCM42, have a more beneficial function regarding skin health and appearance than was previously thought. Appropriate use of formulations derived from symbiotic strains within the skin microbiome can support the development of novel, beneficial topicals. |
doi_str_mv | 10.1111/jocd.15510 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2736303548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2736303548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3930-d475a0906f56a386f495d11de9f51e8fc746cb5558eb18323e4664e6600294573</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EoqWw4QGQJTao0hQ7_kmyRIHyo6JuQIKV5TjXHQ-JPfgmoPI6vCiepnTBAm98dPzdoysfQp5ydsbLeblLbjjjSnF2jxxzWYtNxbW6f6cFOyKPEHeM8brl6iE5ElrUsgwck9_d1mbrZsjhl51DijR5aukYfgDtljn069syUesiIMWlxz24UOQAHuIAsZhztiHSL1-7j7KiNg7UjSEGZ0dqEQFxgjgXWYLntL_xM1yF4lKfMr2CCLl4-K2EbMGO83YNSWUQAz4mD7wdEZ7c3ifk8_mbT927zcXl2_fdq4uNE61gm0HWyrKWaa-0FY32slUD5wO0XnFovKuldr1SqoGeN6ISILWWoDVjVStVLU7IizV3n9P3BXA2U0AH42gjpAVNVZd_Y0LJpqDP_0F3acmxbGfEYQUuqpYV6nSlXE6IGbzZ5zDZfG04M4fqzKE6c1NdgZ_dRi79BMMd-rerAvAV-BlGuP5PlPlw2b1eQ_8Afb6kbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090613290</pqid></control><display><type>article</type><title>Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rhee, Mun Su ; Alqam, Mona L. ; Jones, Brian C. ; Phadungpojna, Sasima ; Day, Doris ; Hitchcock, Thomas M.</creator><creatorcontrib>Rhee, Mun Su ; Alqam, Mona L. ; Jones, Brian C. ; Phadungpojna, Sasima ; Day, Doris ; Hitchcock, Thomas M.</creatorcontrib><description>Background
When formulating topical products to treat skin diseases and addressing general skin health and cosmesis, most of the focus has traditionally been placed on how any given ingredient may impact the structure, function, and health of human skin elements. However, recent research is beginning to highlight the importance of the skin microbiome in relation to certain skin conditions and general cosmesis. Cutibacterium acnes is one of the most prolific skin‐specific bacterial species. Research has shown that the species is divided into subspecies, some of which are thought to be beneficial to the skin. This paper aims to determine the efficacy of strainXYCM42, a C. acnes subspecies defendens derived strain designed to improve the health and appearance of the skin.
Methods
In vitro studies were performed on human keratinocyte and fibroblast monolayers, human peripheral blood mononuclear cells (PBMC), and skin explants to elucidate the effects of live XYCM42 cells and their ferment on human skin cells and tissues. Subsequently, clinical studies were performed using XYCM42‐based topical regimens designed to deliver and support the engraftment of live XYCM42 cells onto subjects' skin. Two studies were performed, a 3‐week pilot study (n = 10) and a 8‐week pivotal study (n = 121). In the latter, 32 subjects were enrolled for an in‐clinic portion for efficacy evaluation, with clinic visits occurring at Baseline, Week 1, Week 4, and Week 8.
Results
In vitro data suggest that XYCM42 and its ferment filtrate have potential to provide benefits to the skin via antioxidant, anti‐inflammatory, and select antimicrobial activities. Clinical observation demonstrated that a XYCM42‐containing regimen supports a healthy skin environment, promotes increased skin hydration, decreases erythema, calms the skin, and regulates sebum production.
Conclusion
These studies provide further evidence that specific strains of C. acnes, such as XYCM42, have a more beneficial function regarding skin health and appearance than was previously thought. Appropriate use of formulations derived from symbiotic strains within the skin microbiome can support the development of novel, beneficial topicals.</description><identifier>ISSN: 1473-2130</identifier><identifier>EISSN: 1473-2165</identifier><identifier>DOI: 10.1111/jocd.15510</identifier><identifier>PMID: 36374551</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Acne ; Acne Vulgaris - drug therapy ; Antioxidants ; Biopsy ; Cutibacterium acnes ; Cytokines ; defendens ; Fibroblasts ; Gene expression ; Humans ; Ingredients ; Keratinocytes ; Leukocytes, Mononuclear ; microbiome ; Peptides ; Pilot Projects ; Propionibacterium acnes ; Skin - microbiology ; Skin Diseases ; skin probiotic ; topical skin products</subject><ispartof>Journal of cosmetic dermatology, 2023-03, Vol.22 (3), p.1031-1045</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC.</rights><rights>2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3930-d475a0906f56a386f495d11de9f51e8fc746cb5558eb18323e4664e6600294573</citedby><cites>FETCH-LOGICAL-c3930-d475a0906f56a386f495d11de9f51e8fc746cb5558eb18323e4664e6600294573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjocd.15510$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjocd.15510$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,11541,27901,27902,45550,45551,46027,46451</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36374551$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rhee, Mun Su</creatorcontrib><creatorcontrib>Alqam, Mona L.</creatorcontrib><creatorcontrib>Jones, Brian C.</creatorcontrib><creatorcontrib>Phadungpojna, Sasima</creatorcontrib><creatorcontrib>Day, Doris</creatorcontrib><creatorcontrib>Hitchcock, Thomas M.</creatorcontrib><title>Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis</title><title>Journal of cosmetic dermatology</title><addtitle>J Cosmet Dermatol</addtitle><description>Background
When formulating topical products to treat skin diseases and addressing general skin health and cosmesis, most of the focus has traditionally been placed on how any given ingredient may impact the structure, function, and health of human skin elements. However, recent research is beginning to highlight the importance of the skin microbiome in relation to certain skin conditions and general cosmesis. Cutibacterium acnes is one of the most prolific skin‐specific bacterial species. Research has shown that the species is divided into subspecies, some of which are thought to be beneficial to the skin. This paper aims to determine the efficacy of strainXYCM42, a C. acnes subspecies defendens derived strain designed to improve the health and appearance of the skin.
Methods
In vitro studies were performed on human keratinocyte and fibroblast monolayers, human peripheral blood mononuclear cells (PBMC), and skin explants to elucidate the effects of live XYCM42 cells and their ferment on human skin cells and tissues. Subsequently, clinical studies were performed using XYCM42‐based topical regimens designed to deliver and support the engraftment of live XYCM42 cells onto subjects' skin. Two studies were performed, a 3‐week pilot study (n = 10) and a 8‐week pivotal study (n = 121). In the latter, 32 subjects were enrolled for an in‐clinic portion for efficacy evaluation, with clinic visits occurring at Baseline, Week 1, Week 4, and Week 8.
Results
In vitro data suggest that XYCM42 and its ferment filtrate have potential to provide benefits to the skin via antioxidant, anti‐inflammatory, and select antimicrobial activities. Clinical observation demonstrated that a XYCM42‐containing regimen supports a healthy skin environment, promotes increased skin hydration, decreases erythema, calms the skin, and regulates sebum production.
Conclusion
These studies provide further evidence that specific strains of C. acnes, such as XYCM42, have a more beneficial function regarding skin health and appearance than was previously thought. Appropriate use of formulations derived from symbiotic strains within the skin microbiome can support the development of novel, beneficial topicals.</description><subject>Acne</subject><subject>Acne Vulgaris - drug therapy</subject><subject>Antioxidants</subject><subject>Biopsy</subject><subject>Cutibacterium acnes</subject><subject>Cytokines</subject><subject>defendens</subject><subject>Fibroblasts</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Ingredients</subject><subject>Keratinocytes</subject><subject>Leukocytes, Mononuclear</subject><subject>microbiome</subject><subject>Peptides</subject><subject>Pilot Projects</subject><subject>Propionibacterium acnes</subject><subject>Skin - microbiology</subject><subject>Skin Diseases</subject><subject>skin probiotic</subject><subject>topical skin products</subject><issn>1473-2130</issn><issn>1473-2165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhS0EoqWw4QGQJTao0hQ7_kmyRIHyo6JuQIKV5TjXHQ-JPfgmoPI6vCiepnTBAm98dPzdoysfQp5ydsbLeblLbjjjSnF2jxxzWYtNxbW6f6cFOyKPEHeM8brl6iE5ElrUsgwck9_d1mbrZsjhl51DijR5aukYfgDtljn069syUesiIMWlxz24UOQAHuIAsZhztiHSL1-7j7KiNg7UjSEGZ0dqEQFxgjgXWYLntL_xM1yF4lKfMr2CCLl4-K2EbMGO83YNSWUQAz4mD7wdEZ7c3ifk8_mbT927zcXl2_fdq4uNE61gm0HWyrKWaa-0FY32slUD5wO0XnFovKuldr1SqoGeN6ISILWWoDVjVStVLU7IizV3n9P3BXA2U0AH42gjpAVNVZd_Y0LJpqDP_0F3acmxbGfEYQUuqpYV6nSlXE6IGbzZ5zDZfG04M4fqzKE6c1NdgZ_dRi79BMMd-rerAvAV-BlGuP5PlPlw2b1eQ_8Afb6kbQ</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Rhee, Mun Su</creator><creator>Alqam, Mona L.</creator><creator>Jones, Brian C.</creator><creator>Phadungpojna, Sasima</creator><creator>Day, Doris</creator><creator>Hitchcock, Thomas M.</creator><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>202303</creationdate><title>Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis</title><author>Rhee, Mun Su ; Alqam, Mona L. ; Jones, Brian C. ; Phadungpojna, Sasima ; Day, Doris ; Hitchcock, Thomas M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3930-d475a0906f56a386f495d11de9f51e8fc746cb5558eb18323e4664e6600294573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acne</topic><topic>Acne Vulgaris - drug therapy</topic><topic>Antioxidants</topic><topic>Biopsy</topic><topic>Cutibacterium acnes</topic><topic>Cytokines</topic><topic>defendens</topic><topic>Fibroblasts</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Ingredients</topic><topic>Keratinocytes</topic><topic>Leukocytes, Mononuclear</topic><topic>microbiome</topic><topic>Peptides</topic><topic>Pilot Projects</topic><topic>Propionibacterium acnes</topic><topic>Skin - microbiology</topic><topic>Skin Diseases</topic><topic>skin probiotic</topic><topic>topical skin products</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rhee, Mun Su</creatorcontrib><creatorcontrib>Alqam, Mona L.</creatorcontrib><creatorcontrib>Jones, Brian C.</creatorcontrib><creatorcontrib>Phadungpojna, Sasima</creatorcontrib><creatorcontrib>Day, Doris</creatorcontrib><creatorcontrib>Hitchcock, Thomas M.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cosmetic dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rhee, Mun Su</au><au>Alqam, Mona L.</au><au>Jones, Brian C.</au><au>Phadungpojna, Sasima</au><au>Day, Doris</au><au>Hitchcock, Thomas M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis</atitle><jtitle>Journal of cosmetic dermatology</jtitle><addtitle>J Cosmet Dermatol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>22</volume><issue>3</issue><spage>1031</spage><epage>1045</epage><pages>1031-1045</pages><issn>1473-2130</issn><eissn>1473-2165</eissn><abstract>Background
When formulating topical products to treat skin diseases and addressing general skin health and cosmesis, most of the focus has traditionally been placed on how any given ingredient may impact the structure, function, and health of human skin elements. However, recent research is beginning to highlight the importance of the skin microbiome in relation to certain skin conditions and general cosmesis. Cutibacterium acnes is one of the most prolific skin‐specific bacterial species. Research has shown that the species is divided into subspecies, some of which are thought to be beneficial to the skin. This paper aims to determine the efficacy of strainXYCM42, a C. acnes subspecies defendens derived strain designed to improve the health and appearance of the skin.
Methods
In vitro studies were performed on human keratinocyte and fibroblast monolayers, human peripheral blood mononuclear cells (PBMC), and skin explants to elucidate the effects of live XYCM42 cells and their ferment on human skin cells and tissues. Subsequently, clinical studies were performed using XYCM42‐based topical regimens designed to deliver and support the engraftment of live XYCM42 cells onto subjects' skin. Two studies were performed, a 3‐week pilot study (n = 10) and a 8‐week pivotal study (n = 121). In the latter, 32 subjects were enrolled for an in‐clinic portion for efficacy evaluation, with clinic visits occurring at Baseline, Week 1, Week 4, and Week 8.
Results
In vitro data suggest that XYCM42 and its ferment filtrate have potential to provide benefits to the skin via antioxidant, anti‐inflammatory, and select antimicrobial activities. Clinical observation demonstrated that a XYCM42‐containing regimen supports a healthy skin environment, promotes increased skin hydration, decreases erythema, calms the skin, and regulates sebum production.
Conclusion
These studies provide further evidence that specific strains of C. acnes, such as XYCM42, have a more beneficial function regarding skin health and appearance than was previously thought. Appropriate use of formulations derived from symbiotic strains within the skin microbiome can support the development of novel, beneficial topicals.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>36374551</pmid><doi>10.1111/jocd.15510</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1473-2130 |
ispartof | Journal of cosmetic dermatology, 2023-03, Vol.22 (3), p.1031-1045 |
issn | 1473-2130 1473-2165 |
language | eng |
recordid | cdi_proquest_miscellaneous_2736303548 |
source | MEDLINE; Wiley Online Library Open Access; Wiley Online Library Journals Frontfile Complete |
subjects | Acne Acne Vulgaris - drug therapy Antioxidants Biopsy Cutibacterium acnes Cytokines defendens Fibroblasts Gene expression Humans Ingredients Keratinocytes Leukocytes, Mononuclear microbiome Peptides Pilot Projects Propionibacterium acnes Skin - microbiology Skin Diseases skin probiotic topical skin products |
title | Characterization of a live Cutibacterium acnes subspecies defendens strain XYCM42 and clinical assessment as a topical regimen for general skin health and cosmesis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T03%3A46%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20a%20live%20Cutibacterium%20acnes%20subspecies%20defendens%20strain%20XYCM42%20and%20clinical%20assessment%20as%20a%20topical%20regimen%20for%20general%20skin%20health%20and%20cosmesis&rft.jtitle=Journal%20of%20cosmetic%20dermatology&rft.au=Rhee,%20Mun%20Su&rft.date=2023-03&rft.volume=22&rft.issue=3&rft.spage=1031&rft.epage=1045&rft.pages=1031-1045&rft.issn=1473-2130&rft.eissn=1473-2165&rft_id=info:doi/10.1111/jocd.15510&rft_dat=%3Cproquest_cross%3E2736303548%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090613290&rft_id=info:pmid/36374551&rfr_iscdi=true |